Gilead Sciences, Inc.
333 Lakeside Drive
Foster City
California
94404
United States
Tel: 800-GILEAD-5 or 650-574-3000
Fax: 650-522-5800
Website: http://www.gilead.com/
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
YEAR FOUNDED:
1987
LEADERSHIP:
CEO: John F. Milligan, PhD
Chief Scientific Officer: Norbert W. Bischofberger, PhD
CFO: Robin L. Washington
COO: Kevin Young
CLINICAL TRIAL:
Please click here for clinical trial information.
1368 articles with Gilead Sciences, Inc.
-
Metracrine, based in San Diego, completed a Series C financing round worth $65 million.
-
Hookipa Biotech and Gilead inked a research collaboration deal to develop and commercialize therapeutics for hepatitis B (HBV) and HIV.
-
Hookipa and Gilead Enter into a Collaboration and License Agreement to Develop Immunotherapies Against HIV and Hepatitis B
6/5/2018
Hookipa and Gilead will jointly develop therapeutics against HIV and Hepatitis B infections; Hookipa and Gilead will jointly research and Hookipa will manufacture arenavirus-based vectors for clinical development by Gilead
-
Kite Announces New Data Analyses for CAR T Therapy in Patients with Blood Cancers at the 2018 American Society of Clinical Oncology Meeting
6/4/2018
Kite, a Gilead Company announced new analyses from the ZUMA chimeric antigen receptor T (CAR T) cell therapy development program that are being presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors
6/4/2018
Kite, a Gilead Company (Nasdaq: GILD), announced results from an ongoing Phase 1 study conducted by the National Cancer Institute (NCI) showing that clinical responses were observed with investigational T cell receptor (TCR) cell therapy targeting human papillomavirus type 16 (HPV-16) E7 in solid tumor cancers caused by HPV.
-
Gilead Sciences Announces Leadership Changes in Corporate Development and Strategy
6/4/2018
Gilead Sciences, Inc. announced the promotion of Andrew Dickinson to Executive Vice President, Corporate Development and Strategy.
-
Primary Endpoint Hit: Gilead and Galapagos’ JAK1 Inhibitor for Arthritis Positive in Phase II
5/31/2018
Gilead Sciences and its development partner Galapagos NV announced positive data from its Phase II EQUATOR trial of filgotinib in psoriatic arthritis. -
Gilead Sciences to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13
5/30/2018
Gilead Sciences, Inc. announced that Robin L. Washington, Gilead’s Executive Vice President and Chief Financial Officer, and John McHutchison, Gilead’s Chief Scientific Officer and Head of Research & Development, will participate in a fireside chat at the Goldman Sachs 39th Annual Global Healthcare Conference.
-
Gilead and Galapagos Announce Results With Filgotinib in the Phase 2 Equator Study in Psoriatic Arthritis and Progression Into Phase 3 for the Selection Study in Ulcerative Colitis
5/30/2018
Gilead Sciences, Inc. and Galapagos NV announced that the randomized, placebo-controlled Phase 2 EQUATOR study of filgotinib, an investigational, selective JAK1 inhibitor, in 131 adults with moderate to severe psoriatic arthritis, achieved its primary endpoint of improvement in the signs and symptoms of psoriatic arthritis at Week 16.
-
There are dollar signs in the treatment of nonalcoholic steatohepatitis (NASH). The market is pegged to hit $25 billion by 2026 and companies are flooding the developmental pipeline with potential treatments for a disease that has no approved therapies in the United States.
-
Brii Biosciences Launches with $260 Million, a Partnership with Vir Biotech, and Other Relationsh...
5/24/2018
Brii Biosciences is launching to accelerate the development and delivery of breakthrough drugs in China with $260 million in financial backing. -
Two months after walking away from his role as head of R&D and chief scientific officer at Gilead Sciences, Norbert Bischofberger has re-emerged at the helm of startup Kronos Bio, Inc.
-
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
-
FDA Calls Out Pharma Companies for Blocking Requests for Samples from Generic Manufacturers
5/18/2018
In order to drive the manufacture of affordable generic drugs, the U.S. Food and Drug Administration is naming names of companies that have attempted to block competition. -
Wednesday was the big day for pharma and biotech companies to unveil abstracts ahead of the annual American Society of Oncology meeting in Chicago next month. Some companies have unveiled positive results that are making investors happy, while others… not so much.
-
U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents
5/15/2018
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)—in combination with safer sex practices—to reduce the risk of sexually acquired HIV-1 in at-risk adolescents. The safety and efficacy profile of Truvada for HIV prevention in uninfected adults, a strategy called pre-exposure prophylaxis (PrEP), is well ...
-
In anticipation of marketing approval in Europe, Gilead Sciences has leased a 117,000 square-foot facility in The Netherlands to manufacture and deliver Yescarta, its CAR-T product, to patients across Europe.
-
Gilead—Down but Not Out?
5/11/2018
You know when an analyst starts an article with, “Gilead’s Q1 financial results were a disaster,” that it requires a closer look. -
AIDS Healthcare Foundation Files Additional Lawsuits Against Gilead over TDF Toxicity Concerns
5/9/2018
Gilead Sciences is facing another round of lawsuits regarding its HIV treatments. This morning the AIDS Healthcare Foundation announced two sets of California-based patients filed a personal injury lawsuit against the Bay Area company regarding safety concerns surrounding its TDF treatment. -
It has been noted that a number of billionaires—at least six—who are fifty years or older in age, have been investing in health care and longevity-related startup companies.